Global Drugs for Respiratory Syncytial Virus (RSV) Market Research Report

Pune, India -- (SBWire) -- 06/26/2020 --The Global Drugs for Respiratory Syncytial Virus (RSV) Market is expected to register a significant CAGR over 4.0% over the forecast period. RSV is a virus that causes respiratory diseases, like bronchiolitis and pneumonia. RSV is the cause of respiratory infections. Overall, the demand for fast diagnostic techniques is increasing in cases of RSV infections. In accordance with the CDC, RSV results in the average number of children hospitalized each year from approximately 1,32,000 to 172,000 under the age of five and the deaths of approximately 14,000 over the age of 65 alone in the USA. Human respiratory syncytial virus (RSV) affects the lungs and blocks breathing passages. Respiratory syncytial virus (RSV) infection is being experienced as a slight cold in healthy people since it can cause serious problems in infants and children with less than age of one year. The increased prevalence of RSV is the guiding factor behind this sector. Because RSV infections' clinical symptoms are indistinguishable from other respiratory infections, a fast, precise and sensitive treatment techniques.

Leading players operating in the market include: Valeant Pharmaceuticals International, GlaxoSmithKline plc., Merck Co., Inc., Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AbbVie, Inc., MEDIVIR AB, AstraZeneca plc., Gilead Sciences, Inc., ReViral Ltd., and Inc.

Sample@ https://www.arcognizance.com/enquiry-sample/1046655

Key factors including increasing prevalence rate of RSV infection among infants and growing interest of varied biotechnology companies to produce recombinant drugs for treatment of RSV infection is driving overall market size. However, soaring prices of prophylaxis drugs and a lack of return on investment in these drugs might challenge market growth to some extent. The respiratory syncytial virus (RSV) has severely infected infants and the elderly and claim more lives than AIDS in nearly each country. Only two antibody drugs are approved for its prevention, and ribavirin, a relatively nonspecific antiviral, is being used for treatment. Many pharmaceutical and biotech companies are initiating research programs against RSV. Together, the R&D accounted for the wide spectrum of drugs, antibodies, synthetic small molecule antiviral and antisense technology, which collectively formed at least 25 active R&D programs. Many companies recently cancelled RSV projects during a prioritization of their R&D portfolios even though there was continuous demand for these drugs.

Europe players are also involved in the development of antibodies which can prevent RSV infection in individuals. For instance, AstraZeneca is involved in development of monoclonal antibody, called SYNAGIS, which will prevent severe infection, available in the injectable form. Key advantage of this injection is that it boost the immunity of the system, thus avoiding the RSV infection.

Purchase@ https://www.arcognizance.com/purchase/1046655

The global Drugs for respiratory syncytial virus (RSV) market is bifurcated on the basis of drugs, dosage form and geography. The drugs segment includes ribavirin and other drug types. The dosage form segment is further divided into injectables, oral and others. On the basis of region, the market is divided into Europe, North America, Asia-Pacific, Latin America and Middle East & Africa. The sterilization technologies market for COVID-19 market has been further divided into key countries. The report overall covers leading 20 countries and regions.

Table of Contents
Chapter One: Market Introduction

Chapter Two: Executive Summary

Chapter Three: Global Drugs for respiratory syncytial virus (RSV) market – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints

Chapter Four: Global Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025 – Drugs
4.1. Ribavirin
4.2. Others

Chapter Five: Global Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025 – Dosage Form
5.1. Injectables
5.2. Oral
5.3. Others

Chapter Six: Global Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025 – By Region
6.1. North America
6.2. Europe
6.3. Asia-Pacific
6.4. Latin America
6.5. Middle East & Africa

Chapter Seven: North America Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025
7.1. North America Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
7.1.1. Ribavirin
7.1.2. Others
7.2. North America Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
7.2.1. Injectables
7.2.2. Oral
7.2.3. Others
7.3. North America Drugs for respiratory syncytial virus (RSV) market – By Country, 2015-2025
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico

Chapter Eight: Europe Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025
8.1. Europe Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
8.1.1. Ribavirin
8.1.2. Others
8.2. Europe Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
8.2.1. Injectables
8.2.2. Oral
8.2.3. Others
8.3. Europe Drugs for respiratory syncytial virus (RSV) market – By Country, 2015-2025
8.3.1. Germany
8.3.2. France
8.3.3. UK
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe

Chapter Nine: Asia-Pacific Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025
9.1. Asia Pacific Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
9.1.1. Ribavirin
9.1.2. Others
9.2. Asia Pacific Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
9.2.1. Injectables
9.2.2. Oral
9.2.3. Others
9.3. Asia-Pacific Drugs for respiratory syncytial virus (RSV) market – By Country, 2015-2025
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Rest of Asia-Pacific

Chapter Ten: Latin America Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025
10.1. LATAM Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
10.1.1. Ribavirin
10.1.2. Others
10.2. LATAM Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
10.2.1. Injectables
10.2.2. Oral
10.2.3. Others
10.3. Latin America Drugs for respiratory syncytial virus (RSV) market – By Country, 2015-2025
10.3.1. Brazil
10.3.2. Rest of Latin America

Chapter Eleven: Middle East & Africa Drugs for respiratory syncytial virus (RSV) market – Analysis and Revenue Forecast, 2015-2025
11.1. MEA Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
11.1.1. Ribavirin
11.1.2. Others
11.2. MEA Drugs for respiratory syncytial virus (RSV) market – By Application, 2015-2025
11.2.1. Injectables
11.2.2. Oral
11.2.3. Medical
11.2.4. Others
11.3. Middle East & Africa Drugs for respiratory syncytial virus (RSV) market – By Country, 2015-2025
11.3.1. UAE
11.3.2. Saudi Arabia
11.3.3. Turkey
11.3.4. Rest of Middle East & Africa

Chapter Twelve: Competitive Analysis
12.1.1. Competition Dashboard
12.1.2. Company Profiles
12.1.2.1. ReViral Ltd
12.1.2.1.1. Company Details
12.1.2.1.2. Drugs Portfolio
12.1.2.1.3. Financial Overview
12.1.2.1.4. Main Business Overview
12.1.2.1.5. News
12.1.2.2. Valeant Pharmaceuticals International
12.1.2.3. GlaxoSmithKline plc.
12.1.2.4. Merck Co., Inc.
12.1.2.5. Teva Pharmaceuticals Industries Ltd.
12.1.2.6. F. Hoffmann-La Roche Ltd.
12.1.2.7. AbbVie, Inc.
12.1.2.8. MEDIVIR AB
12.1.2.9. AstraZeneca plc.
12.1.2.10. Gilead Sciences, Inc.

About Analytical Research Cognizance
Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARC's potential.
ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.